Clinical Trials Logo

Dyslipidemias clinical trials

View clinical trials related to Dyslipidemias.

Filter by:

NCT ID: NCT00665834 Completed - Dyslipidemia Clinical Trials

Comparison of Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome

Start date: April 2006
Phase: Phase 4
Study type: Interventional

This is a 3-month, randomized, parallel-group study with 2 periods, comparing the efficacy and the safety of rosuvastatin 20 mg versus atorvastatin 80 mg in patients with an acute coronary syndrome (ACS).

NCT ID: NCT00664859 Completed - Dyslipidemia Clinical Trials

12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia

Start date: October 2007
Phase: Phase 2/Phase 3
Study type: Interventional

The current study is designed to test the long-term (12-month) safety and efficacy of LCP-AtorFen, a combination of atorvastatin and fenofibrate, in patients with dyslipidemia

NCT ID: NCT00664287 Withdrawn - Dyslipidemia Clinical Trials

Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)

Start date: September 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to test the effect of MK0524A (niacin (+) laropiprant) on lowering bad cholesterol and raising good cholesterol.

NCT ID: NCT00659321 Completed - Metabolic Syndrome Clinical Trials

Efficacy of Nicotine Acid on Dyslipidaemia in Patients With Metabolic Syndrome

Start date: January 2007
Phase: Phase 3
Study type: Interventional

Placebo controlled evaluation of effectiveness of nicotine acid in treatment of postprandial dyslipidemia in patients with metabolic syndrome. Nicotine acid decreases postprandial hyperlipidaemia in patients with metabolic syndrome which reduces the low-grade inflammation and the risk of atherosclerosis.

NCT ID: NCT00654628 Completed - Clinical trials for Hypercholesterolemia

Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients (0653A-172)(COMPLETED)

BRAVO
Start date: August 1, 2007
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the safety and tolerability of ezetimibe/simvastatin in patients newly diagnosed with dyslipidemia.

NCT ID: NCT00654602 Completed - Dyslipidaemia Clinical Trials

48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety

Start date: February 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of rosuvastatin in reducing low density lipoprotein cholesterol levels to internationally recognised goals in subjects with dyslipidaemia.

NCT ID: NCT00654446 Completed - Clinical trials for Fredrickson Type IIa & Type IIb Dyslipidaemia

IIIb 6 Week Open Label Multicentre Rosuvastatin & Simvastatin

Start date: September 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the effects on the kidney of rosuvastatin and simvastatin in subjects with Fredrickson Type IIa & Type IIb Dyslipidaemia

NCT ID: NCT00654225 Completed - Clinical trials for Hypercholesterolemia

Treatment of Hypercholesterolaemia in South Asian Subjects (IRIS)

IRIS
Start date: October 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effect of 6 weeks of treatment with Rosuvastatin with 6 weeks of treatment with Atorvastatin in South Asian subjects with hypercholesterolemia.

NCT ID: NCT00653965 Completed - Clinical trials for Hypercholesterolemia

Treatment of Hypercholesterolaemia in Hispanic Subjects (STARSHIP)

STARSHIP
Start date: May 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effect of 6 weeks of treatment with Rosuvastatin with 6 weeks of treatment with Atorvastatin in Hispanic subjects with hypercholesterolemia

NCT ID: NCT00653744 Completed - Clinical trials for Hypercholesterolemia

Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects(ARIES)

ARIES
Start date: March 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effect of 6 weeks of treatment with Rosuvastatin with 6 weeks of treatment with Atorvastatin in African American subjects with hypercholesterolemia.